Stephen Gottschalk

List of Publications by Year
in descending order

297 papers	14,816 citations	19657 61 h-index	21540 114 g-index
303 all docs	303 docs citations	303 times ranked	13065 citing authors

#	Article	IF	Citations
1	Development of a cGMP-compliant process to manufacture donor-derived, CD45RA-depleted memory CD19-CAR T cells. Gene Therapy, 2023, 30, 222-231.	4.5	4
2	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. European Journal of Cancer, 2022, 160, 112-133.	2.8	24
3	CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. Nature Communications, 2022, 13, 587.	12.8	41
4	Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. Transplantation and Cellular Therapy, 2022, 28, 73.e1-73.e9.	1.2	20
5	Donor-derived multiple leukemia antigenâ€“specific T-cell therapy to prevent relapse after transplantÂin patients with ALL. Blood, 2022, 139, 2706-2711.	1.4	13
6	Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients. Transplantation and Cellular Therapy, 2022, 28, 262.e1-262.e10.	1.2	1
7	A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunology Research, 2022, 10, 512-524.	3.4	12
8	Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy. Frontiers in Oncology, 2022, 12, 845540.	2.8	10
9	Pediatric Patient and Caregiver Reported Symptom Burden, Anxiety, Depression, and Quality of Life during CD19-CAR T-Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, S392.	1.2	0
10	Venetoclax-Based Combination Therapy As a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Children with Relapsed/Refractory AML. Transplantation and Cellular Therapy, 2022, 28, S120-S121.	1.2	1
11	Safety and Tolerability of Administering Leukemia-Specific Donor T Cells (mLSTs) after Allogeneic Transplant to Pediatric Patients with AML/MDS. Transplantation and Cellular Therapy, 2022, 28, S223.	1.2	0
12	Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood, 2022, 140, 16-24.	1.4	14
13	CD45RA Depleted T-Cell Addback and Prophylactic Blinatumomab Administration Following TcrÎ±Î²/CD19-Depleted Haploidentical Transplantation in Pediatric Patients with High Risk Acute Leukemia. Transplantation and Cellular Therapy, 2022, 28, S36.	1.2	0
14	Long Term Follow up for the Development of Subsequent Malignancies in Patients Treated with Genetically Modified Immune Effectors. Transplantation and Cellular Therapy, 2022, 28, S200-S201.	1.2	0
15	CD45RA-Depleted Haploidentical Transplantation Combined with NK Cell Addback Results in Promising Long-Term Outcomes in Pediatric Patients with High-Risk Hematologic Malignancies. Transplantation and Cellular Therapy, 2022, 28, S105.	1.2	0
16	Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL. Transplantation and Cellular Therapy, 2022, 28, S24.	1.2	0
17	B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model. Molecular Cancer Therapeutics, 2022, 21, 999-1009.	4.1	8
18	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. Blood Advances, 2022, 6, 5737-5749.	5.2	20

#	Article	IF	Citations
19	Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models. Frontiers in Immunology, 2022, 13, .	4.8	7
20	CAR TÂcell therapy for solid tumors: Fatal attraction requires adhesion. Med, 2022, 3, 353-354.	4.4	1
21	Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages. Cancer Discovery, 2022, 12, 2098-2119.	9.4	24
22	Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells. Advances in Cell and Gene Therapy, 2021, 4, e99.	0.9	10
23	Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood, 2021, 137, 2585-2597.	1.4	38
24	Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neuro-Oncology, 2021, 23, 999-1011.	1.2	63
25	Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Therapy, 2021, 28, 321-334.	4.6	25
26	Successful SCID gene therapy in infant with disseminated BCG. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 993-995.e1.	3.8	3
27	A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function. Cancer Discovery, 2021, 11, 1661-1671.	9.4	33
28	Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS. Bone Marrow Transplantation, 2021, 56, 1866-1875.	2.4	7
29	CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood, 2021, 138, 318-330.	1.4	98
30	Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. , 2021, 9, e001930.		21
31	Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. Frontiers in Immunology, 2021, 12, 684642.	4.8	57
32	A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells. Frontiers in Immunology, 2021, 12, 691741.	4.8	15
33	Hemophagocytic lymphohistiocytosisâ€like toxicity (carHLH) after CD19â€specific CAR Tâ€cell therapy. British Journal of Haematology, 2021, 194, 701-707.	2.5	61
34	Abstract 1543: Mining cancer-specific isoforms as CAR T-cell therapy targets for pediatric solid and brain tumors. , 2021, , .		1
35	Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models. Cancers, 2021, 13, 4301.	3.7	7
36	Transient blockade of TBK1/IKKÎµ allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors. Cytotherapy, 2021, 23, 787-792.	0.7	6

#	Article	IF	Citations
37	Evidence generation and reproducibility in cell and gene therapy research: A call to action. Molecular Therapy - Methods and Clinical Development, 2021, 22, 11-14.	4.1	13
38	Employing Synthetic T-cell Biology to Target AML without On-Target/Off-Cancer Toxicity. Blood Cancer Discovery, 2021, 2, 559-561.	5.0	0
39	Post-transplant Lymphoproliferative Disease. , 2021, , 265-276.		0
40	Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin. Cancer Immunology Research, 2021, 9, 279-290.	3.4	24
41	Expect the unexpected: piggyBac and lymphoma. Blood, 2021, 138, 1379-1380.	1.4	4
42	CD19-CAR TÂcells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia. Cell Reports, 2021, 37, 110079.	6.4	48
43	Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL. Blood, 2021, 138, 471-471.	1.4	0
44	CD45RA-Depleted Haploidentical Transplantation Combined with NK Cell Addback Results in Promising Long-Term Outcomes in Pediatric Patients with High-Risk Hematologic Malignancies. Blood, 2021, 138, 172-172.	1.4	3
45	CD19-CAR T Cells Develop Exhaustion Epigenetic Programs during a Clinical Response. Blood, 2021, 138, 2782-2782.	1.4	0
46	CD45RO+ T-Cell Add Back and Prophylactic Blinatumomab Administration Post TcrÎ±Î²/CD19-Depleted Haploidentical Transplantation in Pediatric Patients with High Risk Acute Leukemia. Blood, 2021, 138, 2897-2897.	1.4	2
47	Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. , 2021, 9, e003237.		29
48	152â€…Common trajectories of highly effective anti-CD19 chimeric antigen receptor-modified T cells identified by endogenous T cell receptor lineages. , 2021, 9, A160-A161.		0
49	Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Science Translational Medicine, 2021, 13, eabh0272.	12.4	123
50	Unifying heterogeneous expression data to predict targets for CAR-T cell therapy. OncoImmunology, 2021, 10, 2000109.	4.6	1
51	Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. Bone Marrow Transplantation, 2020, 55, 929-938.	2.4	31
52	CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?. Molecular Therapy, 2020, 28, 2320-2339.	8.2	194
53	Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Communications, 2020, 11, 3549.	12.8	103
54	The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing. Molecular Therapy - Methods and Clinical Development, 2020, 18, 571-581.	4.1	13

#	Article	IF	Citations
55	Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28Î¶ T Cells. Molecular Therapy - Oncolytics, 2020, 18, 202-214.	4.4	37
56	Preventing Ubiquitination Improves CAR T Cell Therapy via â€˜CAR Merry-Go-Aroundâ€™. Immunity, 2020, 53, 243-245.	14.3	4
57	Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Molecular Therapy, 2020, 28, 1251-1262.	8.2	89
58	A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy. Frontiers in Oncology, 2020, 10, 262.	2.8	48
59	Second Allogeneic Hematopoietic Cell Transplant Is a Successful Salvage Modality for Pediatric Patients Who Relapse after First Transplant. Biology of Blood and Marrow Transplantation, 2020, 26, S85-S86.	2.0	0
60	Haploidentical CD45RA-Negative Donor Lymphocyte Infusions Are Feasible, Safe and Associated with Clinical Benefit. Biology of Blood and Marrow Transplantation, 2020, 26, S268.	2.0	3
61	Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy. Trends in Immunology, 2020, 41, 665-675.	6.8	42
62	Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond. Children, 2020, 7, 14.	1.5	13
63	Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2020, 26, 911-919.	2.0	8
64	Allogeneic CAR Cell Therapyâ€”More Than a Pipe Dream. Frontiers in Immunology, 2020, 11, 618427.	4.8	64
65	Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s. Advances in Experimental Medicine and Biology, 2020, 1257, 109-131.	1.6	7
66	139â€…Establishment of canine CAR T cells treatment model for solid tumor immunotherapy development. , 2020, , .		2
67	MyD88/CD40 signaling retains CAR T cells in a less differentiated state. JCI Insight, 2020, 5, .	5.0	34
68	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. Blood, 2020, 136, 39-40.	1.4	3
69	Venetoclax Enhances Anti-Leukemia Activity of CD123-Specific BiTE-Secreting T-Cells in AML. Blood, 2020, 136, 12-13.	1.4	3
70	GRP78 Is Expressed on the Cell Surface of Pediatric AML Blasts and Can be Targeted with GRP78-CAR T Cells without Toxicity to Hematopoietic Progenitor Cells. Blood, 2020, 136, 12-12.	1.4	1
71	IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH. Neuro-Oncology, 2020, 22, iii360-iii361.	1.2	0
72	IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL. Neuro-Oncology, 2020, 22, iii360-iii360.	1.2	0

#	Article	IF	Citations
73	EXTH-20. SYNGENEIC B7-H3-SPECIFIC CAR T-CELLS HAVE POTENT ANTI-BRAIN TUMOR ACTIVITY VIA LOCAL OR SYSTEMIC DELIVERY. Neuro-Oncology, 2020, 22, ii91-ii91.	1.2	0
74	Multi-Omic Based Antigen Discovery for the Immunotherapy of Pediatric Acute T Cell Lymphoblastic Leukemia. Blood, 2020, 136, 17-18.	1.4	1
75	EXTH-73. HETEROGENEITY IN CELL SURFACE ANTIGEN AND HLA CLASS I EXPRESSION IN PEDIATRIC BRAIN TUMORS AND ITS IMPACT ON T-CELL IMMUNOTHERAPY. Neuro-Oncology, 2020, 22, ii103-ii103.	1.2	0
76	Autologous CD19-CAR T-Cells for the Treatment of Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients: An initial Report from an Institutional Phase I/II Study. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S265.	0.4	1
77	Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors. Frontiers in Immunology, 2019, 10, 218.	4.8	43
78	IMMU-14. IMPLICATIONS FOR T-CELL IMMUNOTHERAPY: CELL SURFACE ANTIGEN AND HLA class I EXPRESSION IN PEDIATRIC BRAIN TUMORS ARE HETEROGENOUS. Neuro-Oncology, 2019, 21, ii96-ii96.	1.2	1
79	IMMU-13. CRISPR/CAS9-MEDIATED SILENCING OF SHP-1 SIGNIFICANTLY ENHANCES THE ANTI-GLIOMA ACTIVITY OF IL-13RÎ±2 CAR T CELLS. Neuro-Oncology, 2019, 21, ii95-ii96.	1.2	3
80	Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. New England Journal of Medicine, 2019, 380, 1525-1534.	27.0	203
81	Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. Scientific Reports, 2019, 9, 2636.	3.3	38
82	Engineering for Success: Approaches to Improve Chimeric Antigen Receptor TÂCell Therapy for Solid Tumors. Drugs, 2019, 79, 401-415.	10.9	17
83	Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor-Associated Antigens. Biology of Blood and Marrow Transplantation, 2019, 25, S62-S63.	2.0	0
84	Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Advances, 2019, 3, 2689-2695.	5.2	9
85	â€œMiniâ€•bank of only 8 donors supplies CMV-directed T cells to diverse recipients. Blood Advances, 2019, 3, 2571-2580.	5.2	44
86	Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy, 2019, 21, 212-223.	0.7	16
87	NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunology Research, 2019, 7, 363-375.	3.4	180
88	Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinoma. Pediatric Blood and Cancer, 2019, 66, e27469.	1.5	7
89	Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas. Cancer Research, 2019, 79, LB-147-LB-147.	0.9	30
90	Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas. , 2019, , .		2

#	Article	IF	Citations
91	Tandem CAR T cells targeting HER2 and IL13RÎ±2 mitigate tumor antigen escape. Journal of Clinical Investigation, 2019, 129, 3464-3464.	8.2	20
92	CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity. Blood, 2019, 134, 1932-1932.	1.4	3
93	Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing Phase I/II Clinical Study. Blood, 2019, 134, 2058-2058.	1.4	2
94	Enhanced Transduction Lentivector Gene Therapy for Treatment of Older Patients with X-Linked Severe Combined Immunodeficiency. Blood, 2019, 134, 608-608.	1.4	7
95	Targeting ceramide synthase 6â€“dependent metastasis-prone phenotype in lung cancer cells. Journal of Clinical Investigation, 2019, 129, 3464-3464.	8.2	3
96	Engineering Naturally Occurring CD7 Negative Cells for the Immunotherapy of CD7 Positive Leukemia. Blood, 2019, 134, 868-868.	1.4	1
97	Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity. Blood, 2019, 134, 3917-3917.	1.4	1
98	Inducible MyD88 Signaling Enhances the Anti-AML Activity of BiTE-Secreting ENG T-Cells. Blood, 2019, 134, 4441-4441.	1.4	0
99	Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma. Molecular Therapy - Methods and Clinical Development, 2018, 9, 70-80.	4.1	87
100	High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 1643-1650.	2.0	24
101	HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy, 2018, 20, 697-705.	0.7	62
102	Adoptive Transfer of IL13RÎ±2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. Molecular Therapy, 2018, 26, 986-995.	8.2	55
103	Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectivesâ€”A Single-Center Experience, 2008 to 2016. Biology of Blood and Marrow Transplantation, 2018, 24, 1424-1431.	2.0	15
104	CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?. Expert Review of Anticancer Therapy, 2018, 18, 451-461.	2.4	17
105	Advances in immunotherapy for pediatric acute myeloid leukemia. Expert Opinion on Biological Therapy, 2018, 18, 51-63.	3.1	13
106	Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 537-541.	2.0	21
107	Redirecting T cells to hematological malignancies with bispecific antibodies. Blood, 2018, 131, 30-38.	1.4	134
108	The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 830-837.	3.8	20

#	Article	IF	Citations
109	Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 1128-1139.	1.6	137
110	Improving CD123-Targeted T-Cell Therapy for Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, S232.	2.0	1
111	Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells. Frontiers in Medicine, 2018, 5, 343.	2.6	12
112	EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood, 2018, 132, 2351-2361.	1.4	49
113	Infectious Mononucleosis and Other Epstein-Barr Virusâ€“Associated Diseases. , 2018, , 747-759.		0
114	Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. Journal of Nuclear Medicine, 2018, 59, 1894-1900.	5.0	36
115	Sequential Infusion of TcrÎ±Î²- and CD45RA-Depleted Haploidentical Progenitor Cells Is Safe and Allows for Rapid Immune Reconstitution in Pediatric Patients with Recurrent Hematological Malignancies. Blood, 2018, 132, 4574-4574.	1.4	0
116	Armed Oncolytic Adenovirusâ€“Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Research, 2017, 77, 2040-2051.	0.9	170
117	Targeting CD19: the good, the bad, and CD81. Blood, 2017, 129, 9-10.	1.4	10
118	Early and Late Factors Impacting Patient and Graft Outcome in Pediatric Liver Transplantation. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, e53-e59.	1.8	20
119	HER2-Specific Chimeric Antigen Receptorâ€“Modified Virus-Specific T Cells for Progressive Glioblastoma. JAMA Oncology, 2017, 3, 1094.	7.1	608
120	Transgenic Expression of IL15 Improves Antiglioma Activity of IL13RÎ±2-CAR T Cells but Results in Antigen Loss Variants. Cancer Immunology Research, 2017, 5, 571-581.	3.4	232
121	Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Molecular Therapy, 2017, 25, 2440-2451.	8.2	151
122	In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy. Molecular Therapy - Methods and Clinical Development, 2017, 7, 32-41.	4.1	14
123	CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells. Cancer Immunology Research, 2017, 5, 860-870.	3.4	29
124	Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discovery, 2017, 7, 1238-1247.	9.4	204
125	T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Molecular Therapy - Oncolytics, 2017, 6, 69-79.	4.4	26
126	Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models. Cancer Discovery, 2017, 7, 1306-1319.	9.4	125

#	Article	IF	Citations
127	Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Molecular Therapy, 2017, 25, 2202-2213.	8.2	109
128	Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Human Gene Therapy, 2017, 28, 437-448.	2.7	72
129	EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas. Methods in Molecular Biology, 2017, 1532, 255-265.	0.9	16
130	Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 3547-3557.	1.6	367
131	Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma.. Journal of Clinical Oncology, 2017, 35, 10508-10508.	1.6	32
132	Antigen-dependent costimulation to improve T-cell therapy for cancer.. Journal of Clinical Oncology, 2017, 35, 151-151.	1.6	0
133	Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update. Journal of Clinical & Cellular Immunology, 2016, 07, .	1.5	2
134	Tandem CAR T cells targeting HER2 and IL13RÎ±2 mitigate tumor antigen escape. Journal of Clinical Investigation, 2016, 126, 3036-3052.	8.2	515
135	CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Molecular Therapy, 2016, 24, 1615-1626.	8.2	70
136	T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies. Scientific Reports, 2016, 6, 27130.	3.3	52
137	76. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13RÎ±2-CAR T Cells. Molecular Therapy, 2016, 24, S33.	8.2	0
138	Long-Term Organ Function in Children Following Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. Biology of Blood and Marrow Transplantation, 2016, 22, S239-S240.	2.0	0
139	Outcomes after Matched Unrelated Donor Stem Cell Transplantation in Chronic Granulomatous Disease â€“ an Update. Biology of Blood and Marrow Transplantation, 2016, 22, S378.	2.0	0
140	Allogeneic Stem Cell Transplantation in a Pediatric Patient with Whim Syndrome. Biology of Blood and Marrow Transplantation, 2016, 22, S238.	2.0	1
141	IVIG Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant: A Retrospective Analysis of Monthly Intravenous Immunoglobulin Infusion vs. IgG Level Based Dosing. Biology of Blood and Marrow Transplantation, 2016, 22, S244.	2.0	0
142	Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers. Molecular Therapy, 2016, 24, 1511-1512.	8.2	8
143	Respiratory Viral Infections after Hematopoietic Stem Cell Transplants : The Texas Children's Hospital Experience. Biology of Blood and Marrow Transplantation, 2016, 22, S256-S257.	2.0	1
144	Matched Unrelated Allogeneic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia: Texas Children's Hospital Experience. Biology of Blood and Marrow Transplantation, 2016, 22, S237.	2.0	1

#	Article	IF	Citations
145	Intravesicular Cidofovir for BK Hemorrhagic Cystitis in Pediatric Patients after Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2016, 22, S163-S164.	2.0	3
146	Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13RÎ±2-positive Glioma. Molecular Therapy, 2016, 24, 354-363.	8.2	72
147	Safety and Preliminary Efficacy of "Ready to Administer" Cytomegalovirus (CMV)-Specific T Cells for the Treatment of Patients with Refractory CMV Infection. Blood, 2016, 128, 388-388.	1.4	1
148	Two-Pronged Cell Therapy for B-Cell Malignancies: Engineering NK Cells to Target CD22 and Redirect Bystander T Cells to CD19. Blood, 2016, 128, 4560-4560.	1.4	4
149	Fast and Efficient Gene Editing in Human Hematopoietic Cells. Blood, 2016, 128, 4704-4704.	1.4	0
150	Umbilical Cord Blood Transplantation Conditioned without Serotherapy Is an Excellent Curative Alternative for Pediatric Non-Malignant Diseases. Biology of Blood and Marrow Transplantation, 2015, 21, S103-S104.	2.0	0
151	Mixed Donor Chimerism after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biology of Blood and Marrow Transplantation, 2015, 21, S236.	2.0	0
152	Outcomes after Allogeneic Stem Cell Transplantation for Patients with Non-Hodgkin Lymphoma: Texas Children's Hospital Experience 1999-2013. Biology of Blood and Marrow Transplantation, 2015, 21, S211-S212.	2.0	0
153	Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Lymphoma Post Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2015, 21, S148.	2.0	1
154	19. A Phase I Clinical Trial of Autologous HER2 CMV Bispecific CAR T Cells for Progressive Glioblastoma. Molecular Therapy, 2015, 23, S9.	8.2	1
155	282. A scFv-Based CAR To Redirect T Cells To IL13Ra2-Positive Glioma. Molecular Therapy, 2015, 23, S113.	8.2	1
156	721. Safety of Multiple Doses of CAR T Cells. Molecular Therapy, 2015, 23, S288.	8.2	1
157	B7-h3-specific engager T cells for the immunotherapy of pediatric solid tumors. , 2015, 3, .		0
158	Costimulation to enhance the antitumor activity of CD19 eng T cells. , 2015, 3, .		1
159	IM-02 * A scFv-BASED CAR TO REDIRECT T CELLS TO IL13RÂ2-POSITIVE PEDIATRIC GLIOMA. Neuro-Oncology, 2015, 17, iii15-iii15.	1.2	0
160	Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2015, 21, 1266-1272.	2.0	24
161	Administration of LMP-specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive lymphoma post allogeneic stem cell transplant. Cytotherapy, 2015, 17, S18.	0.7	2
162	Safety of multiple doses of car T cells. Cytotherapy, 2015, 17, S12-S13.	0.7	0

#	Article	IF	Citations
163	Human Epidermal Growth Factor Receptor 2 (HER2) â€“Specific Chimeric Antigen Receptorâ€“Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. Journal of Clinical Oncology, 2015, 33, 1688-1696.	1.6	778
164	Response to â€œIn vivo secretion of anti-CD3 Ã— anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagementâ€• Molecular Therapy, 2015, 23, 613.	8.2	1
165	Adoptive T-Cell Immunotherapy. Current Topics in Microbiology and Immunology, 2015, 391, 427-454.	1.1	48
166	Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. Journal of Neuro-Oncology, 2015, 125, 307-315.	2.9	24
167	Adoptive cell therapy for sarcoma. Immunotherapy, 2015, 7, 21-35.	2.0	12
168	The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells. Pharmaceutical Research, 2015, 32, 779-792.	3.5	86
169	Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells. Molecular Therapy, 2015, 23, 171-178.	8.2	78
170	Safety of Multiple Doses of CAR T Cells. Blood, 2015, 126, 4425-4425.	1.4	5
171	Abstract B74: Co-targeting the tumor and its associated vasculature in glioblastoma. , 2015, , .		0
172	Matched Unrelated Allogeneic Stem Cell Transplantation for Patients with Congenital Amegakaryocytic Thrombocytopenia: Texas Children`s Hospital Experience. Blood, 2015, 126, 5529-5529.	1.4	0
173	Foreign or Domestic CARs: Receptor Ligands as Antigen-Binding Domains. Medical Sciences (Basel,) Tj ETQq1 1 0.784314 rgBT /Overl	2.9	4
174	Changing the Mindset in Life Sciences Toward Translation: A Consensus. Science Translational Medicine, 2014, 6, 264cm12.	12.4	42
175	Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma. Molecular Therapy, 2014, 22, 132-139.	8.2	185
176	Harnessing the Immune System to Potentiate Oncolytics. Molecular Therapy, 2014, 22, 239-240.	8.2	1
177	Toward Immunotherapy With Redirected T Cells in a Large Animal Model. Journal of Immunotherapy, 2014, 37, 407-415.	2.4	56
178	CAR T Cells for Solid Tumors. Cancer Journal (Sudbury, Mass), 2014, 20, 151-155.	2.0	170
179	Complementation of Antigen-presenting Cells to Generate T Lymphocytes With Broad Target Specificity. Journal of Immunotherapy, 2014, 37, 193-203.	2.4	42
180	Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. Journal of Clinical Oncology, 2014, 32, 798-808.	1.6	433

#	Article	IF	Citations
181	T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy. Molecular Therapy, 2014, 22, 102-111.	8.2	140
182	Design and development of therapies using chimeric antigen receptorâ€expressing T cells. Immunological Reviews, 2014, 257, 107-126.	6.0	418
183	A New Class of Antigen T-Cells That Redirect Bystander T-Cells to CD19 Positive Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, S71.	2.0	0
184	Umbilical Cord Blood Transplantation Can be an Effective Therapy for Patients with Primary Immunodeficiency Diseases Who Lack an HLA-Matched Related Donor. Biology of Blood and Marrow Transplantation, 2014, 20, S175-S176.	2.0	0
185	Outcome after Allogeneic Stem Cell Transplant for Patients with Hematological Malignancies and Associated Chromosome 7 Deletions. Biology of Blood and Marrow Transplantation, 2014, 20, S178.	2.0	0
186	Outcome after Stem Cell Transplant in Patients with Dyskeratosis Congenita. Biology of Blood and Marrow Transplantation, 2014, 20, S178-S179.	2.0	0
187	Refined/Accelerated T Cell Therapies for the Treatment of EBV+ Lymphomas. Biology of Blood and Marrow Transplantation, 2014, 20, S134.	2.0	0
188	T cells redirected to interleukin-13RÎ±2 with interleukin-13 muteinâ€“chimeric antigen receptors have anti-glioma activity but alsoÂrecognize interleukin-13RÎ±1. Cytotherapy, 2014, 16, 1121-1131.	0.7	68
189	Cell carriers to attack glioma. Cytotherapy, 2014, 16, 871-872.	0.7	0
190	Genetically Modified T-Cell Therapy for Osteosarcoma. Advances in Experimental Medicine and Biology, 2014, 804, 323-340.	1.6	16
191	Synergistic Antitumor Effects of Chimeric Antigen Receptor-Modified T Cells and Oncolytic Virotherapy. Blood, 2014, 124, 5808-5808.	1.4	5
192	Abstract LB-264: Two is better than one: Adoptive T cell therapy targeting tumor antigens and the tumor endothelium potentiates T cell activation and cytolytic activity. , 2014, , .		0
193	Abstract LB-199: A rationally designed bispecific chimeric antigen receptor molecule that simultaneously redirects T cells to target HER2 and GD2 in osteosarcoma. Cancer Research, 2014, 74, LB-199-LB-199.	0.9	1
194	Abstract B8: Adoptive immunotherapy targeting tumor heterogeneity in high-grade glioma (HGG). , 2014, , .		0
195	CD123-Engager T Cells As a Novel Immunotherapeutic for AML. Blood, 2014, 124, 3762-3762.	1.4	0
196	Highlights of the Third International Conference on Immunotherapy in Pediatric Oncology. Pediatric Hematology and Oncology, 2013, 30, 349-366.	0.8	3
197	Is cancer gene therapy an empty suit?. Lancet Oncology, The, 2013, 14, e447-e456.	10.7	48
198	Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation. Blood, 2013, 121, 207-218.	1.4	76

#	Article	IF	Citations
199	Outcomes in Pediatric Patients With Engraftment Failure After Allogeneic Transplants. Biology of Blood and Marrow Transplantation, 2013, 19, S253-S254.	2.0	0
200	Application of Anti-Viral Adoptive T-Cell Therapy to Primary Immunodeficiency Patients. Journal of Allergy and Clinical Immunology, 2013, 131, AB139.	2.9	0
201	Evaluating Donor Lymphocyte Infusions (DLI) for the Treatment of Falling Chimerism, Minimal Residual Disease and Relapse After Pediatric Hematopoietic Stem Cell Transplantation (HSCT). Biology of Blood and Marrow Transplantation, 2013, 19, S195-S196.	2.0	1
202	Outcomes After Second Allogeneic Transplants in Pediatric Patients With Relapsed Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2013, 19, S253.	2.0	0
203	Anti-Tumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma. Biology of Blood and Marrow Transplantation, 2013, 19, S348-S349.	2.0	0
204	T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma. Molecular Therapy, 2013, 21, 629-637.	8.2	200
205	Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma. Molecular Therapy, 2013, 21, 1611-1620.	8.2	266
206	Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Molecular Therapy, 2013, 21, 2113-2121.	8.2	200
207	Targeting EBVâ€™s Achillesâ€™ heel with antigen-specific T cells. Immunotherapy, 2013, 5, 353-355.	2.0	2
208	Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma. Molecular Therapy, 2013, 21, 2087-2101.	8.2	300
209	TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Molecular Therapy - Nucleic Acids, 2013, 2, e105.	5.1	371
210	Genetically Modified T Cells to Target Glioblastoma. Frontiers in Oncology, 2013, 3, 322.	2.8	16
211	A Vaccine That Co-Targets Tumor Cells and Cancer Associated Fibroblasts Results in Enhanced Antitumor Activity by Inducing Antigen Spreading. PLoS ONE, 2013, 8, e82658.	2.5	43
212	Abstract PR16: Genetically engineered T cells redirected against cancer-associated fibroblasts to potentiate immunotherapeutic effects.. , 2013, , .		0
213	Abstract IA26: Stroma-targeted immunotherapy. , 2013, , .		0
214	Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections. Molecular Therapy, 2012, 20, 1622-1632.	8.2	238
215	T-cell-biased immune responses generated by a mucosally targeted adenovirus-Ïƒ1 vaccine. Mucosal Immunology, 2012, 5, 311-319.	6.0	10
216	Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs. Gene Therapy, 2012, 19, 818-827.	4.5	2

#	Article	IF	Citations
217	Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Therapy, 2012, 19, 212-217.	4.6	87
218	A phase II study evaluating the safety and efficacy of an adenovirus-Î”LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Annals of Oncology, 2012, 23, 997-1005.	1.2	110
219	Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma. Journal of Immunotherapy, 2012, 35, 159-168.	2.4	59
220	Interleukin-13 receptor Î±2: glioma's unlucky receptor?. Cytotherapy, 2012, 14, 645-646.	0.7	1
221	Adoptive Transfer of Rapidly-Generated Multivirus-Specific T Cells to Treat Adenovirus, EBV and CMV Infections of Hematopoietic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2012, 18, S219.	2.0	1
222	Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy, 2012, 4, 1129-1138.	2.0	88
223	Aggressive peripheral CD70â€positive tâ€cell lymphoma associated with severe chronic active EBV infection. Pediatric Blood and Cancer, 2012, 59, 758-761.	1.5	5
224	Abstract 3500: T cells redirected against HER2 for the adoptive immunotherapy for HER2-positive osteosarcoma. Cancer Research, 2012, 72, 3500-3500.	0.9	7
225	Safety and Clinical Efficacy of Rapidly-Generated Trivirus-Directed T Cells After Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2012, 120, 223-223.	1.4	25
226	Expansion of T cells targeting multiple antigens of cytomegalovirus, Epsteinâ€“Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy, 2011, 13, 976-986.	0.7	50
227	Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epsteinâ€“Barr virus-associated lymphoma. Cytotherapy, 2011, 13, 518-522.	0.7	25
228	TILling head and neck cancer for cell therapy. Cytotherapy, 2011, 13, 772-773.	0.7	1
229	Stem Cell Transplant for HLH: Single Institution Series. Biology of Blood and Marrow Transplantation, 2011, 17, S263-S264.	2.0	0
230	Haploidentical Stem Cell Transplants in Children With Acute Lymphoblastic Leukemia in First or Second Remission. Biology of Blood and Marrow Transplantation, 2011, 17, S310-S311.	2.0	2
231	Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood, 2011, 117, 5835-5849.	1.4	241
232	T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood, 2011, 117, 4304-4314.	1.4	140
233	Reduced-intensity SCT for chronic active EBV infection: excellent outcomes should trigger future investigations on how EBV-positive recipient cells are eradicated. Bone Marrow Transplantation, 2011, 46, 18-19.	2.4	1
234	Cellular immunotherapy for high-grade glioma. Immunotherapy, 2011, 3, 423-434.	2.0	24

#	Article	IF	Citations
235	PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor. Molecular Therapy, 2011, 19, 2133-2143.	8.2	110
236	A Th1-inducing Adenoviral Vaccine for Boosting Adoptively Transferred T Cells. Molecular Therapy, 2011, 19, 211-217.	8.2	19
237	Cytotoxic T Lymphocytes Simultaneously Targeting Multiple Tumor-associated Antigens to Treat EBV Negative Lymphoma. Molecular Therapy, 2011, 19, 2258-2268.	8.2	80
238	Highlights of the Second International Conference on â€œImmunotherapy in Pediatric Oncologyâ€. Pediatric Hematology and Oncology, 2011, 28, 459-460.	0.8	7
239	Crosstalk between Medulloblastoma Cells and Endothelium Triggers a Strong Chemotactic Signal Recruiting T Lymphocytes to the Tumor Microenvironment. PLoS ONE, 2011, 6, e20267.	2.5	26
240	Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins. Blood, 2011, 118, 956-956.	1.4	1
241	Towards Phase 2/3 Trials for Epstein - Barr Virus (EBV)-Associated Malignancies,. Blood, 2011, 118, 4043-4043.	1.4	0
242	Vaccination with Î”CD40L or Flagellin Gene-Modified T Cells Activates Dendritic Cells In Vivo and Induces a Potent Anti-Tumor Immune Response. Blood, 2011, 118, 1909-1909.	1.4	0
243	Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma. Journal of Immunotherapy, 2010, 33, 983-990.	2.4	201
244	IRAK-M Removal Counteracts Dendritic Cell Vaccine Deficits in Migration and Longevity. Journal of Immunology, 2010, 185, 4223-4232.	0.8	25
245	piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies. Human Gene Therapy, 2010, 21, 427-437.	2.7	124
246	HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors. Clinical Cancer Research, 2010, 16, 474-485.	7.0	324
247	Immunotherapeutic options for Epsteinâ€“Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy, 2010, 2, 663-671.	2.0	13
248	The Costs and Cost-Effectiveness of Allogeneic Peripheral Blood Stem Cell Transplantation versus Bone Marrow Transplantation in Pediatric Patients with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2010, 16, 1272-1281.	2.0	39
249	Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy, 2010, 12, 743-749.	0.7	75
250	Computer-Assisted Quantitative Evaluation of Therapeutic Responses for Lymphoma Using Serial PET/CT Imaging. Academic Radiology, 2010, 17, 479-488.	2.5	12
251	Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution. Leukemia and Lymphoma, 2010, 51, 664-670.	1.3	28
252	Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ÃŸ to Patients with EBV-Associated Lymphomas. Blood, 2010, 116, 560-560.	1.4	5

#	Article	IF	Citations
253	CASPALLO: Phase I Clinical Trial of Allodepleted T Cells Transduced with Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation. Blood, 2010, 116, 559-559.	1.4	1
254	Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression. Molecular Therapy, 2009, 17, 1779-1787.	8.2	171
255	How to design effective vaccines: lessons from an old success story. Expert Review of Vaccines, 2009, 8, 543-546.	4.4	16
256	Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood, 2009, 113, 2442-2450.	1.4	107
257	Comparable Outcome of Alternative Donor and Matched Sibling Donor Hematopoietic Stem Cell Transplant for Children with Acute Lymphoblastic Leukemia in First or Second Remission Using Alemtuzumab in a Myeloablative Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2008, 14, 1245-1252.	2.0	45
258	Successful Treatment of Stem Cell Graft Failure in Pediatric Patients Using a Submyeloablative Regimen of Campath-1H and Fludarabine. Biology of Blood and Marrow Transplantation, 2008, 14, 1298-1304.	2.0	21
259	Clinical and Virological Characteristics of Patients with Chronic Active Epsteinâ€Barr Virus Infection Treated with Hematopoietic Stem Cell Transplantation: Insights and Questions. Clinical Infectious Diseases, 2008, 46, 1535-1536.	5.8	2
260	EBV Lymphoproliferative Disease after Transplantation. , 2008, , 449-465.		0
261	Complete Tumor Responses in Lymphoma Patients Who Receive Autologous Cytotoxic T Lymphocytes Targeting EBV Latent Membrane Proteins. Blood, 2008, 112, 230-230.	1.4	0
262	Dendritic Cell Function After Gene Transfer with Adenovirus-calcium Phosphate Co-precipitates. Molecular Therapy, 2007, 15, 386-392.	8.2	20
263	Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells. Cancer Research, 2007, 67, 5957-5964.	0.9	153
264	Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood, 2007, 110, 2838-2845.	1.4	266
265	A Single Institution Experience With Pediatric Nasopharyngeal Carcinoma: High Incidence of Toxicity Associated With Platinum-based Chemotherapy Plus IMRT. Journal of Pediatric Hematology/Oncology, 2007, 29, 500-505.	0.6	23
266	Contact-activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T cells. Journal of Immunotherapy, 2007, 30, 96-107.	2.4	23
267	81: Enhancing the in vivo expansion of adoptively transferred EBV-CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Biology of Blood and Marrow Transplantation, 2007, 13, 32-33.	2.0	0
268	252: Outcome of allogeneic hematopoietic stem cell transplantation for pediatric patients with chronic myeloid leukemia. Biology of Blood and Marrow Transplantation, 2007, 13, 92-93.	2.0	0
269	T-Cells Redirected Against CD70 for the Immunotherapy of Hematological Malignancies.. Blood, 2007, 110, 2757-2757.	1.4	3
270	In vivoexpansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leukemia and Lymphoma, 2006, 47, 837-842.	1.3	27

#	Article	IF	Citations
271	Administration of Latent Membrane Protein 2â€“Specific Cytotoxic T Lymphocytes to Patients with Relapsed Epstein-Barr Virusâ€“Positive Lymphoma. Clinical Lymphoma and Myeloma, 2006, 6, 342-347.	1.4	19
272	Activation of LMP1- and LMP2-specific T-cells for the immunotherapy of EBV positive malignancies with an adenoviral vector encoding full length LMP1 and LMP2. Biology of Blood and Marrow Transplantation, 2006, 12, 16-17.	2.0	0
273	Outcome of alternative donor transplantation for severe aplastic anemia can be comparable to outcome with matched related donors. Biology of Blood and Marrow Transplantation, 2006, 12, 26-27.	2.0	1
274	Comparable Outcomes of Matched-Related and Alternative Donor Stem Cell Transplantation for Pediatric Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2006, 12, 1277-1284.	2.0	96
275	Treatment of solid organ transplant recipients with autologous Epstein Barr virusâ€“specific cytotoxic T lymphocytes (CTLs). Blood, 2006, 108, 2942-2949.	1.4	241
276	766. Immunotherapy for Her2-Positive Medulloblastoma: Regression of Experimental Tumors by Transfer of Her2-Redirected T Cells In Vivo. Molecular Therapy, 2006, 13, S296.	8.2	0
277	Improving Immunotherapy Targeted at Subdominant Tumor Antigens. Journal of Immunotherapy, 2005, 28, 614.	2.4	0
278	Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumorâ€“reactive cytotoxic T lymphocytes. Blood, 2005, 105, 2436-2442.	1.4	51
279	Adoptive Immunotherapy for EBV-associated Malignancies. Leukemia and Lymphoma, 2005, 46, 1-10.	1.3	104
280	Post-Transplant Lymphoproliferative Disorders. Annual Review of Medicine, 2005, 56, 29-44.	12.2	395
281	Chronic active Epstein-Barr virus infection of natural killer cells presenting as severe skin reaction to mosquito bites. Journal of Allergy and Clinical Immunology, 2005, 116, 470-472.	2.9	17
282	Outcome of Alternative Donor Transplantation for Severe Aplastic Anemia Can Be Comparable to Outcome with Matched Related Donors.. Blood, 2005, 106, 2052-2052.	1.4	0
283	Transplantation from Matched Unrelated Donors (MUD) for Thalassemia and Other Congenital Red Cell Disorders.. Blood, 2005, 106, 2746-2746.	1.4	0
284	The Use of Autologous LMP2-Specific Cytotoxic T Lymphocytes (CTL) for the Treatment of Relapsed EBV-Positive Hodgkin Disease and Non-Hodgkin Lymphoma.. Blood, 2005, 106, 773-773.	1.4	0
285	The Generation and Characterization of LMP2-Specific CTLs for Use as Adoptive Transfer From Patients With Relapsed EBV-Positive Hodgkin Disease. Journal of Immunotherapy, 2004, 27, 317-327.	2.4	96
286	EBV Lymphoproliferative Disease After Transplantation. , 2004, , 259-270.		0
287	LMP2-Cytotoxic T Lymphocyte Therapy for Relapsed EBV Positive Lymphoma.. Blood, 2004, 104, 3276-3276.	1.4	2
288	Retrovirus-Transduced T Cell Blasts Have Not Only Antigen-Presenting Capabilities but Also Suppressor Regulatory T Cell-Inducing Capability.. Blood, 2004, 104, 3855-3855.	1.4	0

#	Article	IF	Citations
289	Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood, 2003, 101, 1905-1912.	1.4	182
290	Large-Scale Expansion of Dendritic Cell-Primed Polyclonal Human Cytotoxic T-Lymphocyte Lines Using Lymphoblastoid Cell Lines for Adoptive Immunotherapy. Journal of Immunotherapy, 2003, 26, 241-256.	2.4	59
291	Killing 2 birds with 1 stone. Blood, 2003, 102, 4253-4254.	1.4	0
292	Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Advances in Cancer Research, 2002, 84, 175-201.	5.0	53
293	Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy, 2002, 4, 433-434.	0.7	5
294	An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood, 2001, 97, 835-843.	1.4	249
295	Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. International Journal of Cancer, 2001, 93, 706-713.	5.1	80
296	Nonviral Gene Delivery Using Dna: Synthetic Peptide Complexes. Medical Science Symposia Series, 1996, , 337-345.	0.0	0
297	Targeting of Lysosomal Acid Phosphatase with Altered Carbohydrate. Biological Chemistry Hoppe-Seyler, 1989, 370, 75-80.	1.4	18